Novel BTK Inhibitor for Chronic Hives Wins in Phase III Trial

(MedPage Today) -- ANAHEIM, Calif. -- Treatment with remibrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, led to fast improvement in symptom control for patients with chronic spontaneous urticaria (CSU) inadequately controlled...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news